Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

106.49
-1.3000-1.21%
Post-market: 106.490.00000.00%19:37 EDT
Volume:1.01M
Turnover:108.82M
Market Cap:9.39B
PE:-52.98
High:110.00
Open:108.85
Low:105.71
Close:107.79
52wk High:110.18
52wk Low:14.51
Shares:88.17M
Float Shares:80.98M
Volume Ratio:1.19
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:9.83
PE(LYR):-53.91

Loading ...

Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?

Simply Wall St.
·
Aug 20

LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 15

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)

TIPRANKS
·
Aug 13

Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)

TIPRANKS
·
Aug 11

Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares

Reuters
·
Aug 11

Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa

MT Newswires Live
·
Aug 10

Spyre Therapeutics Announces Launch of Spy772 Program and Initiation of Phase 2 Skylight Trial in Hidradenitis Suppurativa

THOMSON REUTERS
·
Aug 10

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

GlobeNewswire
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

TIPRANKS
·
Aug 08

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Aug 08

Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million

Reuters
·
Aug 06

Spyre Therapeutics Inc : Jefferies Raises Target Price to $122 from $98

THOMSON REUTERS
·
Aug 05

Spyre Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026

Reuters
·
Aug 05

Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 05

Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim

TIPRANKS
·
Jul 25

Movement Alert|Spyre Therapeutics Rises 11.41% in Regular Trading, Trading at $104.42

Market Focus
·
Jul 15

Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding?

Simply Wall St.
·
Jul 10

Movement Alert|Spyre Therapeutics Rises 5.02% in Regular Trading, Trading at $93.51

Market Focus
·
Jul 08